Why the study?
Are CMR tissue biomarkers useful in identifying traditional cancer therapy-related cardiac dysfunction (CTRCD) risk in women with ERBB2-positive breast cancer receiving anthracycline and trastuzumab?
Are CMR tissue biomarkers useful in identifying traditional cancer therapy-related cardiac dysfunction (CTRCD) risk in women with ERBB2-positive breast cancer receiving anthracycline and trastuzumab?
Transient increases in CMR tissue biomarkers of inflammation and edema during anthracycline and trastuzumab therapy do not predict traditional cancer therapy-related cardiac dysfunction.
Answers are grounded in this paper and cite their sources.
CMR tissue biomarkers should not guide CTRCD monitoring in this population; leaves open their role in detecting subclinical remodeling.
In women with ERBB2-positive breast cancer receiving sequential anthracycline and trastuzumab therapy, CMR tissue biomarkers suggest inflammation and edema peaking early during therapy and were associated with ventricular remodeling and BNP elevation. However, the increases in CMR biomarkers were transient, were not associated with LVEF or myocardial strain, and were not useful in identifying traditional CTRCD risk.
No takes yet. Share an insight, caveat, or question.
Thavendiranathan et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: